Case Studies in Myeloproliferative Neoplasms

Prithviraj Bose, MD, reviews the case of a 57-year-old man diagnosed with polycythemia vera.

Experts in MPN discuss diagnostic considerations for polycythemia vera.

Dr. Ruben Mesa and panel discuss the importance of and methods for risk assessment in patients with polycythemia vera.

Jamile Shammo, MD, reviews initial treatment options for patients with low risk polycythemia vera.

Experts in polycythemia vera discuss decision-making around when to initiate cytoreductive therapy in patients with low risk polycythemia vera.

Dr Prithviraj Bose reviews treatment options in the setting of hydroxyurea failure in patients with polycythemia vera.

Prithviraj Bose, MD, and colleagues discuss treatment options for high risk polycythemia vera.

Experts in polycythemia vera review data regarding the role of symptomatic improvement in overall outcome in patients with polycythemia vera.

Dr Jamile Shammo reviews the case of a 72-year-old man with primary myelofibrosis.

Jamile Shammo, MD, reviews prognostic models in myelofibrosis.

Experts in MPN review data on predictors of response to ruxolitinib in high risk myelofibrosis.

Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.

Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.

Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.

Stephen Oh, MD, PhD, reviews the case of a 46-year-old female with essential thrombocythemia.

Dr Stephen Oh discusses risk assessment in patients with essential thrombocythemia.

Experts in essential thrombocythemia discuss approaches to individualizing therapy.

Ruben Mesa, MD, and panel discuss the role of molecular profile in treatment decision-making.

Experts in essential thrombocythemia review first line treatment options.

Stephen Oh, MD, PhD, discusses the nuances of identifying disease progression vs transformation in patients with essential thrombocythemia.